AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$WGS

Feeley Kevin sold $364K of WGS

Feeley Kevin (CHIEF FINANCIAL OFFICER) sold 3,728 shares of GeneDx Holdings Corp. (WGS) at an average of $97.61 ($94.26–$99.00, $0.36M total) across 5 trades on 2026-09-16.

Original reporting
SEC EDGAR · Feeley Kevin
Published Sep 18, 2026, 8:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$WGS
Bearish
medium confidence
Mentioned
$WGS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WGSBearishLow
01

Why it matters

The CFO's sale reduces his ownership but remains a significant stake, likely causing limited price movement.

02

Market read

Small insider sale with modest market relevance; may cause slight short-term price pressure.

03

What to watch

Potential upcoming corporate actions or personal tax planning not disclosed.

Relevance 4/10Novelty 5/10Timing: post-market Sep 16, filed Sep 18

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$WGSBearishMedium confidence
Context

CFO Kevin Feeley sold 3,728 shares for $363,892, reducing his stake to 44,945 shares.

Expected impact

Potential slight dip in WGS price over the next few days.

Evidence & confidence

A $364K sale by a senior officer represents a modest reduction; market may view it as neutral to slightly bearish.

Market effects

Sector

Minimal impact on the genetic testing sector; similar insider sales are common.

Regional

Limited to U.S. markets where WGS trades.

Global

Low; no broader market effect.

Counterpoint

What could challenge this read

The sale could be routine liquidity need, not a negative signal.

Key entities

  • Company
    GeneDx Holdings Corp.

    Provider of genetic testing services, ticker WGS.

  • Executive
    Kevin Feeley

    Chief Financial Officer of GeneDx.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

WGS insider trading history →

Related articles

MedAI 8/10

GeneDx (WGS) Q2 2026 Earnings Call Transcript

GeneDx reported Q2 2026 revenue of $114.4 million, up 11% year over year, with exome and genome revenue of $100.3 million (+17%). Adjusted net income was $0.4 million and adjusted diluted EPS $0.01. Q3 revenue guidance is $122 million to $124 million, and full-year 2026 revenue guidance is $475 million to $490 million.

aol.com
$PLTRMed

After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR

Investing.com’s after-hours movers report highlights Palantir (PLTR) up 10% after Q2 EPS of $0.41 and $1.94B revenue, with 2026 revenue guidance raised to $8.15–$8.158B. Snap (SNAP) rose 9.6% on Q2 revenue $1.6B and Q3 guidance $1.7–$1.74B. Backblaze (BLZE) gained 16% on Q2 beat and raised 2026 revenue to $172–$174M. ON (ON) +5%, ICHR -11%, WGS -7%, WHR -4%.

investing.com
$WGSHighAI 9/10

GeneDx Reports Second Quarter 2026 Financial Results

GeneDx Holdings Corp. (WGS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 GeneDx Reports Second Quarter 2026 Financial Results • Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue • Reported exome and genome volume growth of 32% year-over-year • Reported adjusted gross margin (1) of

SEC EDGAR 8-K